Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | Director | August 28, 2024 | September 10, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TriSalus Life Sciences, Inc.
Report date August 28, 2024 · Filed September 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Varka LLC | 247,176 |
Reported balance
After 2024-08-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-08-28 · Sale · Disposed 9 · Balance 247,176 F1: The shares are held by Varka LLC. The Reporting Person may be deemed to have beneficial ownership of the shares held directly by Varka LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by Varka LLC. The Reporting Person may be deemed to have beneficial ownership of the shares held directly by Varka LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2024 Filed Sep 10, 2024 21:42 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | SaleCommon Stock | 9 | $5.50 | $49.50 |
DisclosureSEC source: 0001415889-24-023167 · form4-09102024_090904.xml · nonDerivative · entry 1 Martin George Kelly · CIK 0001982607 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Varka LLC Disclosed balance after: 247,176 F1 · balance_after: The shares are held by Varka LLC. The Reporting Person may be deemed to have beneficial ownership of the shares held directly by Varka LLC. Read SEC document |
| August 13, 2024 Filed Aug 22, 2024 00:43 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector stock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001415889-24-021950 · form4-08222024_120845.xml · derivative · entry 1 Martin George Kelly · CIK 0001982607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-08-12 F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:54 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-23-045692 · doc4.xml · derivative · entry 1 Martin George Kelly · CIK 0001982607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-08-09 F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.